Experts Predict FHLC Will Hit $81
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Source: NASDAQ.COM
Fidelity MSCI Health Care Index ETF Analysis: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $81.28, indicating a potential upside of 15.88% from its current trading price of $70.14.
Notable Holdings with Upside Potential: Key underlying holdings of FHLC, such as Xeris Biopharma Holdings (XERS), Mineralys Therapeutics (MLYS), and iRadimed Corp (IRMD), show significant upside potential based on analyst target prices, with XERS at 38.16% higher, MLYS at 21.59%, and IRMD at 17.06%.
Analyst Target Price Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets relative to current prices could lead to potential downgrades if they are based on outdated information.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analysts' targets in light of recent developments in the companies and the healthcare industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRMD
Wall Street analysts forecast IRMD stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 92.940
Low
98.00
Averages
99.00
High
100.00
Current: 92.940
Low
98.00
Averages
99.00
High
100.00
About IRMD
IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories and services. Its MRidium 3860+ MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Iradimed Founder Sells 7,500 Shares in Strategic Move
- Sale Overview: Roger Susi, founder and CEO of Iradimed, sold 7,500 shares between May 18 and 19, 2026, at a weighted average price of approximately $87.64, totaling around $657,000, which represents 0.17% of his total holdings.
- Holding Analysis: After the transaction, Susi retains 4,397,950 indirect shares, indicating his continued confidence in the company, and this sale is part of a multi-year programmatic reduction in indirect holdings, reflecting his keen awareness of market dynamics.
- Trading Plan Context: The share sale was executed under a Rule 10b5-1 trading plan adopted by Susi in November 2025, aimed at avoiding accusations of insider trading, which underscores the compliance and transparency of his transactions.
- Company Performance: Iradimed reported $22 million in revenue for Q1 2026, a 13% year-over-year increase, while diluted earnings per share rose 22% to $0.45, demonstrating strong performance in the medical device sector and further bolstering investor confidence.
See More
Iradimed Founder Indirectly Sells 7,500 Shares
- Transaction Overview: Roger E. Susi, Founder and CEO of Iradimed, indirectly sold 7,500 shares of common stock on May 18 and 19, 2026, for approximately $657,000, leaving him with 4,397,950 shares, indicating confidence in the company's future.
- Historical Trading Pattern: The sale of 7,500 shares aligns with Susi's historical trading cadence, averaging 21.6 trades per year with typical sell tranches between 5,000 and 10,000 shares, reflecting a consistent divestment strategy since May 2023.
- Company Financial Performance: As of May 2026, Iradimed reported a trailing twelve-month revenue of $86.28 million and a net income of $23.61 million, with a stock price increase of 82.77% over the past year, showcasing strong growth in the medical device sector.
- Investor Confidence: This transaction was executed under a Rule 10b5-1 trading plan adopted by Susi in November 2025 to avoid insider trading allegations, and with over 4 million shares retained post-sale, it underscores his ongoing confidence in the company's prospects.
See More
IRADIMED Reports 13% Revenue Growth in Q1 2026
- Financial Performance Boost: IRADIMED reported Q1 2026 revenue of $21.98 million, reflecting a 13% increase, with net income reaching $5.82 million and earnings per share of $0.45, showcasing strong performance in the MRI-compatible medical device market.
- Adjusted Earnings Growth: The adjusted net income stood at $6.36 million, or $0.49 per share, compared to $5.34 million and $0.42 per share in the prior year, indicating sustained improvement in profitability and bolstering investor confidence.
- Optimistic Future Outlook: The company expects Q2 2026 revenue between $20.0 million and $21.0 million, with diluted earnings per share projected at $0.40 to $0.44, and adjusted earnings per share at $0.44 to $0.48, reflecting stable growth potential.
- Dividend Distribution Plan: IRADIMED declared a quarterly cash dividend of $0.20 per share, payable on May 29, 2026, which enhances shareholder returns and reflects the company's confidence in future cash flows.
See More
Iradimed Surges 4.45% After Strong Quarterly Earnings Beat Expectations
- Significant Revenue Growth: Iradimed's first-quarter revenue increased by 13% to nearly $22 million, surpassing analyst expectations of $20.8 million, indicating strong performance in the MRI equipment market.
- Improved Profitability: The company's net income rose by 24% to over $5.8 million, with non-GAAP earnings per share increasing by 17% to $0.49, both exceeding market forecasts and reflecting ongoing improvements in profitability.
- Successful Product Launch: The new IV pump system, model 3870, was commercially launched during the quarter, with the CEO noting encouraging customer reception and strong early order activity, suggesting significant future sales potential.
- Optimistic Outlook: Iradimed maintained its revenue guidance of $91 million to $96 million and adjusted earnings per share forecast of $2.06 to $2.21, demonstrating confidence in future growth, particularly as aging populations drive increased demand for medical care.
See More
IRadimed Reports Strong Q1 2026 Earnings with Revenue Growth
- Significant Revenue Growth: IRadimed reported Q1 2026 revenue of $22 million, reflecting a 13% increase over Q1 2025, demonstrating solid execution across product lines, particularly from the 3860 pump system and the growing Ferro-magnetic Detection System.
- Product Transition Trends: CEO Susi highlighted that the average selling price (ASP) for the 3870 pump is showing an initial lift closer to 20%, exceeding the anticipated 10% to 14%, with over half of new business coming from Quad four-pump systems, indicating strong market demand for the new product.
- Robust Profitability: The company achieved a gross profit of $16.8 million with a gross margin of 77% in Q1, and net income was $5.8 million, or $0.45 per diluted share, showcasing effective cost control and profitability.
- Optimistic Outlook: For Q2 2026, the company expects revenue between $20 million and $21 million, with a full-year revenue target of $91 million to $96 million; despite short-term production constraints, management remains optimistic about long-term growth prospects.
See More
Iradimed Reports First Quarter Earnings Growth
- Significant Earnings Growth: Iradimed Corporation reported a net income of $5.82 million for the first quarter, translating to an earnings per share (EPS) of $0.45, which marks a substantial increase from last year's $4.69 million and $0.37 per share, reflecting enhanced competitiveness in the market.
- Adjusted Earnings Performance: Excluding special items, the company reported adjusted earnings of $6.36 million, or $0.49 per share, indicating strengthened core business resilience and improved profitability.
- Strong Revenue Growth: The company's revenue rose 12.7% year-over-year to $21.98 million, up from $19.51 million last year, demonstrating sustained market demand that has driven sales growth.
- Optimistic Future Outlook: Iradimed provided guidance for next quarter's EPS in the range of $0.44 to $0.48, and full-year EPS guidance of $2.06 to $2.21, showcasing the company's confidence in future performance and ongoing growth potential.
See More
Iradimed Founder Sells 7,500 Shares in Strategic Move
- Sale Overview: Roger Susi, founder and CEO of Iradimed, sold 7,500 shares between May 18 and 19, 2026, at a weighted average price of approximately $87.64, totaling around $657,000, which represents 0.17% of his total holdings.
- Holding Analysis: After the transaction, Susi retains 4,397,950 indirect shares, indicating his continued confidence in the company, and this sale is part of a multi-year programmatic reduction in indirect holdings, reflecting his keen awareness of market dynamics.
- Trading Plan Context: The share sale was executed under a Rule 10b5-1 trading plan adopted by Susi in November 2025, aimed at avoiding accusations of insider trading, which underscores the compliance and transparency of his transactions.
- Company Performance: Iradimed reported $22 million in revenue for Q1 2026, a 13% year-over-year increase, while diluted earnings per share rose 22% to $0.45, demonstrating strong performance in the medical device sector and further bolstering investor confidence.
See More
Iradimed Founder Indirectly Sells 7,500 Shares
- Transaction Overview: Roger E. Susi, Founder and CEO of Iradimed, indirectly sold 7,500 shares of common stock on May 18 and 19, 2026, for approximately $657,000, leaving him with 4,397,950 shares, indicating confidence in the company's future.
- Historical Trading Pattern: The sale of 7,500 shares aligns with Susi's historical trading cadence, averaging 21.6 trades per year with typical sell tranches between 5,000 and 10,000 shares, reflecting a consistent divestment strategy since May 2023.
- Company Financial Performance: As of May 2026, Iradimed reported a trailing twelve-month revenue of $86.28 million and a net income of $23.61 million, with a stock price increase of 82.77% over the past year, showcasing strong growth in the medical device sector.
- Investor Confidence: This transaction was executed under a Rule 10b5-1 trading plan adopted by Susi in November 2025 to avoid insider trading allegations, and with over 4 million shares retained post-sale, it underscores his ongoing confidence in the company's prospects.
See More
IRADIMED Reports 13% Revenue Growth in Q1 2026
- Financial Performance Boost: IRADIMED reported Q1 2026 revenue of $21.98 million, reflecting a 13% increase, with net income reaching $5.82 million and earnings per share of $0.45, showcasing strong performance in the MRI-compatible medical device market.
- Adjusted Earnings Growth: The adjusted net income stood at $6.36 million, or $0.49 per share, compared to $5.34 million and $0.42 per share in the prior year, indicating sustained improvement in profitability and bolstering investor confidence.
- Optimistic Future Outlook: The company expects Q2 2026 revenue between $20.0 million and $21.0 million, with diluted earnings per share projected at $0.40 to $0.44, and adjusted earnings per share at $0.44 to $0.48, reflecting stable growth potential.
- Dividend Distribution Plan: IRADIMED declared a quarterly cash dividend of $0.20 per share, payable on May 29, 2026, which enhances shareholder returns and reflects the company's confidence in future cash flows.
See More
Iradimed Surges 4.45% After Strong Quarterly Earnings Beat Expectations
- Significant Revenue Growth: Iradimed's first-quarter revenue increased by 13% to nearly $22 million, surpassing analyst expectations of $20.8 million, indicating strong performance in the MRI equipment market.
- Improved Profitability: The company's net income rose by 24% to over $5.8 million, with non-GAAP earnings per share increasing by 17% to $0.49, both exceeding market forecasts and reflecting ongoing improvements in profitability.
- Successful Product Launch: The new IV pump system, model 3870, was commercially launched during the quarter, with the CEO noting encouraging customer reception and strong early order activity, suggesting significant future sales potential.
- Optimistic Outlook: Iradimed maintained its revenue guidance of $91 million to $96 million and adjusted earnings per share forecast of $2.06 to $2.21, demonstrating confidence in future growth, particularly as aging populations drive increased demand for medical care.
See More
IRadimed Reports Strong Q1 2026 Earnings with Revenue Growth
- Significant Revenue Growth: IRadimed reported Q1 2026 revenue of $22 million, reflecting a 13% increase over Q1 2025, demonstrating solid execution across product lines, particularly from the 3860 pump system and the growing Ferro-magnetic Detection System.
- Product Transition Trends: CEO Susi highlighted that the average selling price (ASP) for the 3870 pump is showing an initial lift closer to 20%, exceeding the anticipated 10% to 14%, with over half of new business coming from Quad four-pump systems, indicating strong market demand for the new product.
- Robust Profitability: The company achieved a gross profit of $16.8 million with a gross margin of 77% in Q1, and net income was $5.8 million, or $0.45 per diluted share, showcasing effective cost control and profitability.
- Optimistic Outlook: For Q2 2026, the company expects revenue between $20 million and $21 million, with a full-year revenue target of $91 million to $96 million; despite short-term production constraints, management remains optimistic about long-term growth prospects.
See More
Iradimed Reports First Quarter Earnings Growth
- Significant Earnings Growth: Iradimed Corporation reported a net income of $5.82 million for the first quarter, translating to an earnings per share (EPS) of $0.45, which marks a substantial increase from last year's $4.69 million and $0.37 per share, reflecting enhanced competitiveness in the market.
- Adjusted Earnings Performance: Excluding special items, the company reported adjusted earnings of $6.36 million, or $0.49 per share, indicating strengthened core business resilience and improved profitability.
- Strong Revenue Growth: The company's revenue rose 12.7% year-over-year to $21.98 million, up from $19.51 million last year, demonstrating sustained market demand that has driven sales growth.
- Optimistic Future Outlook: Iradimed provided guidance for next quarter's EPS in the range of $0.44 to $0.48, and full-year EPS guidance of $2.06 to $2.21, showcasing the company's confidence in future performance and ongoing growth potential.
See More
